According to analysts from Barclays, the price target for AstraZeneca (LON: AZN) has been established at £125 ($151.85), which was included in a report that was made public on Friday. These findings were cited in the Borsen Zeitung. Barclays has predicted that the company’s price will go up by 11.23 percent from its most recent closing price, which is reflected in the price they think it will reach.
AZN is now in possession of reports originally compiled by several other equity analysts. These reports were acquired in recent times. According to research released on December 15th by JPMorgan Chase & Co., the price target assigned to the share price of AstraZeneca was set at £125 ($151.85). In a research report released on November 22nd, Berenberg Bank reaffirmed its “buy” rating on shares of AstraZeneca and set a price objective of £118 ($143.34) on the company’s stock. Deutsche Bank Aktiengesellschaft projected that the price of a share of AstraZeneca would rise to £130 ($157.92) within the next twelve months in a published research study on Thursday, December 15th. UBS Group placed a price objective of £101 ($122.69) on AstraZeneca shares in a research report published on November 10th, and the report was made available to the public. A research report published on December 9th by Shore Capital contained an analysis in which the firm reaffirmed its “buy” rating on shares of AstraZeneca. In contrast to the seven financial analysts who gave the stock a buy rating, only one of the analysts polled recommended maintaining the stock’s current holdings. According to Bloomberg, the current average price objective for AstraZeneca is reported to be £113.35 ($137.69), and the current consensus rating for the company is “Moderate Buy.”
A decrease of GBP 68 ($0.83) was applied to an AZN share on Friday, bringing the total price to £112.38 ($136.52). The company only traded 399,357 shares, a significantly lower number than the typical 2,030,130 shares. As a result, a debt-to-equity ratio comes in at 88.97%, a quick ratio comes in at 0.59, a current ratio comes in at 0.81, and a quick ratio comes in at 0.59. The company’s market value is equivalent to 174.14 billion pounds, and its price-to-earnings ratio is 10,702.86. At the moment, the share price of the company is trading at £107.47, which is higher than its 200-day moving average price, which is currently at £106.13. The current price of AstraZeneca represents a one-year high of £115.40 ($140.18), while the current price of GBX 8,214 ($99.78) represents a one-year low.
AstraZeneca PLC is a biopharmaceutical company specializing in the research and development of prescription medications and their manufacture, distribution, and marketing. Oncology-related medications manufactured by the company that is currently available include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex. Crestor, Evrenzo, Farxiga, Forxiga, Brilinta, Brilique, Bydureon, Byetta, BCise, Crestor, and Komboglyze are some of the available medications. Other options include Brilinta, Brilique, and pany, which specializes in the research and development of prescription medications and their manufacture, distribution, and marketing. Oncology-related medications manufactured by the company that is currently available include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex. Crestor, Evrenzo, Farxiga, Forxiga, Brilinta, Brilique, Bydureon, Byetta, BCise, Crestor, and Komboglyze are some of the available medications. Other options include Brilinta, Brilique, Bydureon, and Forxiga.
Discussion about this post